Site-specific differences in Nectin-4 expression and associated immune contexture in advanced urothelial carcinoma: implications for Nectin-4-targeted ADCs
Therapeutic Advances in Medical Oncology
Published online on July 07, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Nectin-4 is a key therapeutic target of antibody–drug conjugates (ADCs) in advanced urothelial carcinoma (UC), but its expression patterns and underlying biology across anatomical sites remain poorly understood.Objectives:This study aimed to ...
Background:Nectin-4 is a key therapeutic target of antibody–drug conjugates (ADCs) in advanced urothelial carcinoma (UC), but its expression patterns and underlying biology across anatomical sites remain poorly understood.Objectives:This study aimed to ...